| __timestamp | BioCryst Pharmaceuticals, Inc. | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 72471000 |
| Thursday, January 1, 2015 | 13047000 | 89204000 |
| Friday, January 1, 2016 | 11253000 | 106010000 |
| Sunday, January 1, 2017 | 13933000 | 137905000 |
| Monday, January 1, 2018 | 29514000 | 159888000 |
| Tuesday, January 1, 2019 | 37121000 | 158425000 |
| Wednesday, January 1, 2020 | 67929000 | 200677000 |
| Friday, January 1, 2021 | 118818000 | 304759000 |
| Saturday, January 1, 2022 | 159371000 | 377221000 |
| Sunday, January 1, 2023 | 213894000 | 336361000 |
Unlocking the unknown
In the competitive landscape of biopharmaceuticals, understanding financial trends is crucial. Over the past decade, Supernus Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Supernus Pharmaceuticals consistently outpaced BioCryst, with SG&A expenses peaking at approximately 336 million in 2023, a 364% increase from 2014. In contrast, BioCryst's expenses grew by a staggering 2,768% over the same period, reaching around 214 million in 2023. This rapid growth reflects BioCryst's aggressive expansion and investment in administrative capabilities. Meanwhile, Supernus's steady increase highlights a more controlled growth strategy. These trends offer a window into each company's strategic priorities and market positioning, providing valuable insights for investors and industry analysts alike.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Johnson & Johnson vs BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? GSK plc or Supernus Pharmaceuticals, Inc.
Biogen Inc. and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Bio-Techne Corporation vs Supernus Pharmaceuticals, Inc.
Comparing SG&A Expenses: Catalent, Inc. vs Supernus Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Catalent, Inc. and BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Pharming Group N.V. vs BioCryst Pharmaceuticals, Inc.
Grifols, S.A. or Supernus Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Ionis Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Merus N.V. and Supernus Pharmaceuticals, Inc.
HUTCHMED (China) Limited vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends